The glioblastoma treatment landscape is projected to grow significantly by 2034 - driven by increased adoption of standard-of-care therapies and the rise of novel, science-driven approaches. This momentum has been further energized by Merck’s landmark acquisition of Modifi Bio, sparking renewed hope in a field long challenged by limited investment and clinical breakthroughs.

Looking ahead to 2026, sustaining this progress is critical. The 7th Glioblastoma Drug Development Summit is your essential platform to accelerate new treatments and unlock the future of glioblastoma care.

Join us for a definitive 3-day summit featuring groundbreaking content and six deep-dive workshops, where you’ll connect with over 90 leading experts from biotech, pharma, and investment. Together, we’ll explore:

• Innovating novel combination strategies to overcome resistance and improve efficacy
• Building robust preclinical and clinical frameworks to accelerate translation
• Mobilizing investment and collaboration to bring promising therapies to patients faster
• Harnessing AI’s transformative role in glioblastoma research and development
• Join leading organizations, including Laminar Pharma, Medicenna, Merck, AstraZeneca, CNS Pharmaceuticals, Imvax, Tactical Therapeutics and many more!

Together, we’ll unlock actionable insights, forge powerful partnerships, and move closer to delivering transformative therapies for one of the most devastating and underserved cancers.